In the open study of ATH434 the volumetrics seems to be an excellent measurement evaluating the progression of neurodegeneration. Correspondingly volumetric measures will be used when evaluating AD drugs. Now the degeneration of cholinergic nerves will be measured by volumetric, not dopaminergic degeneration as in PD.
Forebrain atrophy in early AD, by Masters et al, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $20.98M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $8.974K | 2.100M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 114 | 100472819 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15167315 | 10 |
View Market Depth
| Last trade - 16.10pm 22/07/2024 (20 minute delay) ? |
| ATH (ASX) Chart |